Exchange: NASDAQ·Updated 07:30 PM EST

NGNE News

News
all
press releases
Neurogene Inc. (NASDAQ:NGNE) Stock Rated "Buy" by Sell-Side Analysts
Shares of Neurogene Inc. (NASDAQ:NGNE - Get Free Report) have been given a consensus rating of "Buy" by the eight ratings firms that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, five have assigned a buy recommendation and two have i...
MarketBeat
Neurogene Inc. (NASDAQ:NGNE) Stock Rated "Buy" by Sell-Side Analysts
Shares of Neurogene Inc. (NASDAQ:NGNE - Get Free Report) have been given a consensus rating of "Buy" by the eight ratings firms that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, five have assigned a buy recommendation and two have i...
MarketBeat
More News
The average of price targets set by Wall Street analysts indicates a potential upside of 203.3% in Neurogene (NGNE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced third quarter 2026 financial results and highlighted recent corporate updates. During the third quarter, we...
Business Wire
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Companys Board of Directors approved the grant of non-qualified stock...
Business Wire
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the following conferences: Guggenheim 3rd Annual Healthcare...
Business Wire
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, will present data related to its NGN-401 gene therapy program for Rett syndrome at the European Society of Gene and Cell Therapy...
Business Wire
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that it will present data from its NGN-401 gene therapy program for Rett syndrome at the European Society of Gene...
Business Wire
ACAD's Nuplazid and Daybue drive revenue growth, with rising demand, new formulations and European expansion offering opportunities amid growing competition.
Zacks
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Companys Board of Directors approved the grant of non-qualified stock...
Business Wire
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the H.C. Wainwright 28th Annual Global Investment Conference. Format...
Business Wire

Advertisement|Remove ads.